Saturday 17 October 2026
Export ALPS’s income statement to Excel — free account
Alps Group Inc.
ALPS Healthcare Biotechnology
Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025. In the quarter to September 2025, EPS fell 609.4% and free cash flow fell 26.5%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow ALPS
| Older periods | Mar '25 | Jun '25 | Sep '25 | Mar '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
14.32% | 19.73% | 25.50% | — | |
| (8.18%) | (12.10%) | (17.24%) | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | — | |
Return on Tangible Assets |
19.75% | 25.68% | 31.93% | — | |
Free Cash Flow per Share |
(0.38) | (0.26) | (0.28) | — | |
Free Cash Flow |
(1.31) | (0.91) | (0.96) | — | |
| Other line items | |||||
Cash ROIC |
12.34% | 7.79% | 8.16% | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.09 | 0.05 | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Interest Coverage |
(3.26) | (1.51) | (1.13) | — | |
Operating CF/Net income |
0.98 | 0.45 | 0.35 | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | — | |
Operating CF per Share |
(0.38) | (0.26) | (0.28) | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates